Yahong Pharmaceutical: Abnormal fluctuations in stock trading, there are no undisclosed major events that should be disclosed.

Yahong Pharmaceuticals announced that the company's stock had deviated by 30% in closing prices over three consecutive trading days on March 4th, 5th and 6th, 2026, indicating abnormal fluctuations. After self-examination and consultation with the controlling shareholder and actual controller, as of the date of the announcement, the company has no major undisclosed issues that should be disclosed, and its production and operation are currently normal. In the fiscal year 2025, the company's net loss attributable to parent company was 4.19 billion yuan, and the non-recurring net loss was 4.40 billion yuan, both increasing year-on-year. The company reminds investors to pay attention to investment risks.